Abbott India Ltd - Company Profile
Powered by 
All the sales intelligence you need on Abbott India Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Abbott India Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Abbott India Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Abbott India Ltd (Abbott India), a subsidiary of Abbott Laboratories, develops, manufactures, and distributes science-based nutritional products, diagnostic tools, branded generic pharmaceuticals, and diabetes and vascular devices. The company's major activities revolve around translating science into lasting contributions to health, with a focus on diverse therapeutic areas such as women's health, gastroenterology, cardiology, metabolic disorders, and primary care. Its product portfolio encompasses multi-speciality drugs, vitamins, and products for the treatment of epilepsy, hypothyroidism, vertigo, migraine, and depression. The company’s offerings also include vaccines for influenza, typhoid, and diarrhoea. Abbott India develops pharmaceuticals in various formulations, including tablets, injectables, liquids, ointments, granules, powder, and capsules. The product range helps treat gynaecological, gastroenterological, urological, and neurological diseases, diabetes, pain, and infection. The company has a manufacturing facility in Goa, India. Abbott India is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
16th Floor, Godrej BKC, Plot – C, G Block, Bandra-Kurla Complex, Mumbai, Maharashtra, 400051
Website
www.abbott.co.in
Telephone
91 22 50461000
No of Employees
3,659
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ABBOTINDIA (NSE)
Revenue (2025)
$795.3M
8.1%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
9.7%
(2025 vs 2024)
Market Cap*
$5.7B
Net Profit Margin (2025)
XYZ
1.5%
(2025 vs 2024)
* As of and is in US$
Abbott India Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Allergy: | Arachitol |
| Solspre | Brufen |
| Ebasil | Cremaffin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In July, the company introduced Digene Insta On The Go, a ready-to-use, water-free antacid solution. |
| 2025 | Contracts/Agreements | In June, the company and MSD Pharmaceuticals entered into a partnership for the distribution of the anti-diabetic drug sitagliptin and its combinations in India. |
| 2024 | New Products/Services | In November, the company unveiled its 14-valent pneumococcal conjugate vaccine, PneumoShield 14, in India. |
Competitor Comparison
| Key Parameters | Abbott India Ltd | Dr. Reddy's Laboratories Ltd | Aurobindo Pharma Ltd | Cipla Ltd | Lupin Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Mumbai | Hyderabad | Hyderabad | Mumbai | Mumbai |
| State/Province | Maharashtra | Telangana | Telangana | Maharashtra | Maharashtra |
| No. of Employees | 3,659 | 26,944 | 9,107 | 30,313 | 19,021 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Maithilee Pathare Mistry | Chief Financial Officer | Senior Management | 2025 | - |
| Munir Shaikh | Chairman | Non Executive Board | 2001 | 51 |
| Kartik Rajendran | Director; Managing Director | Executive Board | 2025 | 47 |
| Jejoe Karankumar | Director - Medical Affairs | Senior Management | - | - |
| Richa Tripathi | Associate Director, Sales Force Effectiveness and Project Management Office | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer